SMMT Quote, Financials, Valuation and Earnings

Bristol-Myers Squibb has a net margin of -- compared to Summit Therapeutics's net margin of 21.93%. Summit Therapeutics's return on equity of -- beat Bristol-Myers Squibb's return on equity of 32.01%.

Summit Therapeutics has a consensus price target of $34.52, signalling upside risk potential of 22.09%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $57.01 which suggests that it could grow by 20.85%. Given that Summit Therapeutics has higher upside potential than Bristol-Myers Squibb, analysts believe Summit Therapeutics is more attractive than Bristol-Myers Squibb.

Summit Therapeutics has a beta of -1.012, which suggesting that the stock is 201.24% less volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.363, suggesting its less volatile than the S&P 500 by 63.75%.

Summit Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol-Myers Squibb offers a yield of 5.22% to investors and pays a quarterly dividend of $0.62 per share. Summit Therapeutics pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out -54.35% of its earnings as a dividend.

Summit Therapeutics quarterly revenues are --, which are smaller than Bristol-Myers Squibb quarterly revenues of $11.2B. Summit Therapeutics's net income of -$62.9M is lower than Bristol-Myers Squibb's net income of $2.5B. Notably, Summit Therapeutics's price-to-earnings ratio is -- while Bristol-Myers Squibb's PE ratio is 17.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics is 21,515.21x versus 2.01x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -- compared to Summit Therapeutics's net margin of 32.71%. Summit Therapeutics's return on equity of -- beat Merck &'s return on equity of 39.02%.

Summit Therapeutics has a consensus price target of $34.52, signalling upside risk potential of 22.09%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 23.48%. Given that Merck & has higher upside potential than Summit Therapeutics, analysts believe Merck & is more attractive than Summit Therapeutics.

Summit Therapeutics has a beta of -1.012, which suggesting that the stock is 201.24% less volatile than S&P 500. In comparison Merck & has a beta of 0.389, suggesting its less volatile than the S&P 500 by 61.063%.

Summit Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.88% to investors and pays a quarterly dividend of $0.81 per share. Summit Therapeutics pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Summit Therapeutics quarterly revenues are --, which are smaller than Merck & quarterly revenues of $15.5B. Summit Therapeutics's net income of -$62.9M is lower than Merck &'s net income of $5.1B. Notably, Summit Therapeutics's price-to-earnings ratio is -- while Merck &'s PE ratio is 12.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics is 21,515.21x versus 3.27x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Summit Therapeutics's net margin of 21.63%. Summit Therapeutics's return on equity of -- beat Pfizer's return on equity of 8.72%.

Summit Therapeutics has a consensus price target of $34.52, signalling upside risk potential of 22.09%. On the other hand Pfizer has an analysts' consensus of $29.23 which suggests that it could grow by 18.77%. Given that Summit Therapeutics has higher upside potential than Pfizer, analysts believe Summit Therapeutics is more attractive than Pfizer.

Summit Therapeutics has a beta of -1.012, which suggesting that the stock is 201.24% less volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

Summit Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.91% to investors and pays a quarterly dividend of $0.43 per share. Summit Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Summit Therapeutics quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $13.7B. Summit Therapeutics's net income of -$62.9M is lower than Pfizer's net income of $3B. Notably, Summit Therapeutics's price-to-earnings ratio is -- while Pfizer's PE ratio is 17.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics is 21,515.21x versus 2.25x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Revolution Medicines has a net margin of -- compared to Summit Therapeutics's net margin of --. Summit Therapeutics's return on equity of -- beat Revolution Medicines's return on equity of --.

Summit Therapeutics has a consensus price target of $34.52, signalling upside risk potential of 22.09%. On the other hand Revolution Medicines has an analysts' consensus of $72.25 which suggests that it could grow by 88.15%. Given that Revolution Medicines has higher upside potential than Summit Therapeutics, analysts believe Revolution Medicines is more attractive than Summit Therapeutics.

Summit Therapeutics has a beta of -1.012, which suggesting that the stock is 201.24% less volatile than S&P 500. In comparison Revolution Medicines has a beta of 1.063, suggesting its more volatile than the S&P 500 by 6.289%.

Summit Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revolution Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics pays -- of its earnings as a dividend. Revolution Medicines pays out -- of its earnings as a dividend.

Summit Therapeutics quarterly revenues are --, which are smaller than Revolution Medicines quarterly revenues of --. Summit Therapeutics's net income of -$62.9M is higher than Revolution Medicines's net income of -$213.4M. Notably, Summit Therapeutics's price-to-earnings ratio is -- while Revolution Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics is 21,515.21x versus -- for Revolution Medicines. Usually stocks with elevated PS ratios are considered overvalued.